NASDAQ: QTTBQ32 Bio Inc Stock Ownership - Who owns Q32 Bio?
Insider buying vs selling
Have Q32 Bio Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Shelia M. Violette | Chief Scientific Officer | 2026-02-25 | 2,815 | $4.51 | $12.71kSell |
| Jodie Pope Morrison | CEO | 2026-02-25 | 9,896 | $4.51 | $44.67kSell |
| Lee Kalowski | CFO and President | 2026-02-25 | 3,995 | $4.51 | $18.03kSell |
| Jodie Pope Morrison | CEO | 2025-12-02 | 22,506 | $3.46 | $77.87kSell |
| Lee Kalowski | CFO and President | 2025-12-02 | 9,072 | $3.46 | $31.40kSell |
| Lee Kalowski | CFO and President | 2025-08-26 | 4,240 | $1.80 | $7.64kSell |
| Shelia M. Violette | Chief Scientific Officer | 2025-08-26 | 2,990 | $1.80 | $5.38kSell |
| Jodie Pope Morrison | CEO | 2025-08-26 | 10,494 | $1.80 | $18.90kSell |
QTTB insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when QTTB insiders and whales buy or sell their stock.
QTTB Shareholders
What type of owners hold Q32 Bio Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Arch Venture Fund VIII LP | 39.43% | 5,768,694 | $38.53M | Insider |
| James E. Flynn | 27.94% | 4,087,305 | $27.30M | Insider |
| Diyong Xu | 15.40% | 2,252,987 | $15.05M | Insider |
| Orbimed Advisors LLC | 15.40% | 2,252,987 | $15.05M | Institution |
| Orbimed Advisors LLC | 15.40% | 2,252,987 | $15.05M | Insider |
| Atlas Venture Life Science Advisors LLC | 14.30% | 2,092,106 | $13.98M | Institution |
| Atlas Venture Fund X LP | 14.30% | 2,092,106 | $13.98M | Insider |
| David S. Grayzel | 14.30% | 2,092,106 | $13.98M | Insider |
| Carlyle Group Inc | 7.54% | 1,102,741 | $7.37M | Institution |
| Mahendra Shah | 6.22% | 909,742 | $6.08M | Insider |
QTTB vs Biotech Stocks
Q32 Bio Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.